Costa Rica vs Kuwait: Statin use vs. average non-HDL cholesterol levels
Costa Rica
3.7
in 2018
Kuwait
3.7
in 2018
Costa Rica rank
12th
Kuwait rank
12th
Statin use vs. average non-HDL cholesterol levels over time
- Costa Rica
- Kuwait
How they compare
Costa Rica currently reports 3.7 against 3.7 in Kuwait, a difference of 0.
The two have swapped places 6 times across 39 shared years of data; in 1980 it was Kuwait ahead.
Costa Rica ranks 12th and Kuwait ranks 12th of 191 countries.
Across the 4 decades both report, Costa Rica averaged higher in 1 and Kuwait in 3.
Head to head by decade
| Decade | Costa Rica | Kuwait | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.66 | 4.28 | 0.62 | Kuwait |
| 1990s | 3.89 | 4.18 | 0.29 | Kuwait |
| 2000s | 4 | 4.01 | 0.01 | Kuwait |
| 2010s | 3.84 | 3.79 | 0.0556 | Costa Rica |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Costa Rica or Kuwait?
- Costa Rica, at 3.7 against 3.7 in Kuwait as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Costa Rica and Kuwait?
- 0, with Costa Rica ahead.
- How many years of comparable data are there for Costa Rica and Kuwait?
- 39 years are reported by both, from 1980 to 2018.
- How do Costa Rica and Kuwait rank globally for statin use vs. average non-hdl cholesterol levels?
- Costa Rica ranks 12th and Kuwait ranks 12th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.